Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytotoxic Edema: Pathophysiology

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.

Journal of immunotherapy and precision oncology·2023

Same author

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.

Cancer·2023

Same author

Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors.

Cancer medicine·2022

Same author

Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors.

Scientific reports·2022

Same author

Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022

Same author

Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.

Clinical lung cancer·2022

Same journal

Comparative Distribution of High-Risk Human Papillomavirus (HPV) Genotypes in India vs World Health Organization Regions and Countries: Implications for HPV Vaccination.

Ochsner journal·2026

Same journal

Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.

Ochsner journal·2026

Same journal

A History of Vena Cava Interruption to Treat Pulmonary Embolism: The Ben Hogan Case.

Ochsner journal·2026

Same journal

Type 1 Collagen/Poly-L-Lactic Acid Biocomposite Augmentation of a Nontraumatic Symptomatic Complete Rotator Cuff Tear.

Ochsner journal·2026

Same journal

Spurious Plasma Adrenocorticotropic Hormone Level in a Patient With Adrenal Cushing Syndrome.

Ochsner journal·2026

Same journal

Revumenib-Induced QTc Prolongation Leading to Multiple Episodes of Torsades de Pointes and Ventricular Arrhythmias.

Ochsner journal·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

Pemetrexed and communicating hydrocephalus.

Chang O Son¹, Frank E Mott²

¹Department of Hematology-Oncology, Ochsner Clinic Foundation, New Orleans, LA.

Ochsner Journal

|June 19, 2014

Summary

This summary is machine-generated.

Pemetrexed maintenance therapy for lung cancer may rarely cause communicating hydrocephalus. This case highlights the importance of monitoring for unexpected toxicities during long-term cancer treatment.

Keywords:

Adenocarcinoma of the lung hydrocephalus pemetrexed

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Related Experiment Videos

Last Updated: Apr 28, 2026

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Area of Science:

Oncology
Neurology

Background:

Pemetrexed (Alimta) is a key chemotherapy agent used in combination with platinum for mesothelioma and lung adenocarcinoma.
It is also utilized as a single-agent maintenance therapy for non-small cell lung cancer after initial platinum-based treatment.

Observation:

A patient undergoing maintenance pemetrexed therapy for advanced lung adenocarcinoma developed communicating hydrocephalus.
This neurological complication was unexpected in the context of pemetrexed treatment.

Findings:

This case represents a potentially novel association between pemetrexed maintenance therapy and the development of communicating hydrocephalus.
No prior reports document this specific adverse event linked to pemetrexed.

Implications:

As pemetrexed use, particularly in maintenance settings, becomes more widespread, clinicians should be vigilant for rare or unexpected toxicities.
This finding suggests that communicating hydrocephalus may be a rare but possible adverse effect to consider in the long-term management of patients receiving pemetrexed.
Further surveillance may be warranted to understand the incidence and mechanisms of this potential pemetrexed-associated toxicity.